跳至主要内容
临床试验/NCT03514030
NCT03514030Unknown不适用

Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China

Beijing Tongren Hospital1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2018年4月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
400
试验地点
1
主要终点
misdiagnosis rate

研究概览

简要总结

In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other persons found highly specific AQP4(aquaporin 4)antibodies in NMO patients'sera, and further differentiated between NMO and MS, confirming that NMO is an independent disease.At present, NMO has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.In 2015, the international NMO diagnostic team developed the diagnostic criteria based on highly specific AQP4 antibodie.Up to now, in China, there is no data on the number of NMOSD patients, the rate of misdiagnosis, the treatment methods, and the prognosis.This study is committed to build China's NMOSD big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • more than 14 years old
  • Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015

排除标准

  • less than 14 years old
  • NOT Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015

结局指标

主要结局

misdiagnosis rate

时间窗: 3 years

misdiagnosis rate of NMOSD

次要结局

未报告次要终点

研究者

发起方
Beijing Tongren Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Clinic Registry Study of Optic Neuromyelitis... | 临床试验